JHVEPhoto/iStock Editorial via Getty Images
- Johnson & Johnson (NYSE:JNJ) said that a phase 2/3 trial of nipocalimab for myasthenia gravis met its primary endpoint in adolescents between 12 and 17 years old.
- Patients treated with nipocalimab plus standard of care saw a reduction in total
